HCV drug from Gilead shows efficacy in late-stage trial

02/20/2013 | Yahoo

Patients with certain genotypes of hepatitis C who took Gilead Sciences' sofosbuvir in a late-stage clinical trial had cure rates of 50% at 12 weeks and 73% at 16 weeks, compared with the 25% historic cure rate among such patients. Sofosbuvir-treated patients with cirrhosis showed lower sustained virologic response, researchers said.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX